Menei Philippe, Capelle Laurent, Guyotat Jacques, Fuentes Stéphane, Assaker Richard, Bataille Benoit, François Patrick, Dorwling-Carter Didier, Paquis Philippe, Bauchet Luc, Parker Fabrice, Sabatier Jean, Faisant Nathalie, Benoit Jean-Pierre
Department of Neurosurgery, Institut National de la Santé et de la Recherche Médicale, Unite 646, University Hospital, Angers, France.
Neurosurgery. 2005 Feb;56(2):242-8; discussion 242-8. doi: 10.1227/01.neu.0000144982.82068.a2.
This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma.
Patients were randomized on clinical and radiological assumption of supratentorial high-grade glioma. All patients underwent surgery, and after resection and histological confirmation, patients randomized to Arm A received multiple injections of microsphere suspension (130 mg of 5-fluorouracil). Conventional fractionated radiotherapy (59.4 Gy) was initiated between the second and the seventh day after surgery for both arms.
A total of 95 patients were randomized. Seventy-seven patients were treated and analyzed in intention to treat for efficacy and safety. Overall survival was 15.2 months in Arm A and 13.5 months in Arm B. In the subpopulation of patients with complete resection, overall survival was 15.2 months in Arm A versus 12.3 months in Arm B. However, these differences were not significant. Safety was acceptable with prophylactic high doses of corticosteroids.
It may be hypothesized that the implantation of 5-fluorouracil-loaded microspheres in the wall of the cavity resection did increase the overall survival, but the present study was not designed and sufficiently powered to demonstrate this.
本研究是一项随机、多中心的II期试验,比较在高级别胶质瘤全切术后患者中,围手术期植入5-氟尿嘧啶缓释微球后早期放疗(A组)与单纯早期放疗(B组)的效果。
根据幕上高级别胶质瘤的临床和影像学表现对患者进行随机分组。所有患者均接受手术,在切除并经组织学确认后,随机分配至A组的患者接受多次微球混悬液注射(含130mg 5-氟尿嘧啶)。两组均在术后第2天至第7天开始进行常规分割放疗(59.4Gy)。
共有95例患者被随机分组。77例患者接受了治疗,并按意向性治疗分析疗效和安全性。A组的总生存期为15.2个月,B组为13.5个月。在完全切除的患者亚组中,A组的总生存期为15.2个月,B组为12.3个月。然而,这些差异并不显著。预防性使用高剂量皮质类固醇时,安全性可接受。
可以推测,在腔隙切除壁中植入载有5-氟尿嘧啶的微球确实提高了总生存期,但本研究并非为此设计,且样本量不足以证明这一点。